MPC-25-Osteo for spinal fusion is a proprietary Phase 3-ready product candidate. All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million MPCs delivered on a collagen ceramic carrier material into the disc space with stabilizing hardware.
Disease Indication and Patient Population
A spinal fusion surgery is designed to stop the motion at a painful vertebral segment in order to decrease pain generated from the joint.
According to the Millennium Research Group, in the United States there were approximately 392,000 thoracolumbar spinal fusion procedures performed in 2012 of which lumbar fusion procedures form a significant part1.
MPC-25-Osteo
All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million mesenchymal precursor cells (MPCs) delivered on a collagen ceramic carrier material into the disc space with stabilizing hardware. MPC-25-Osteo is a tier 2 product candidate.
Mechanism of Action
Preclinical studies have established that MPCs have anti-inflammatory effects and secrete multiple paracrine factors that stimulate new proteoglycan and collagen synthesis by chondrocytes in vitro and by resident cells in the nucleus and annulus in vivo. MPCs have also been shown to produce anti-inflammation factors. Together these effects offer the potential to strengthen the load bearing function of the disc by improving disc anatomy and stability, while also reducing inflammation and pain.
Clinical Trials
Phase 3-Ready
Preparation is ongoing for an MPC-25-Osteo Phase 3 trial for the treatment of lumbar spinal fusion.
We view MPC-25-Osteo as a potential collaboration or partnership opportunity. We intend to continue analysis of strategic options for further development.
Phase 2
A Phase 2 study has been completed where MPC-25-Osteo was implanted into the intervertebral disc space of 24 patients undergoing 1 or 2-level lumbar interbody fusion via posterior procedures. Click here for trial results.
_________________________________________________
1US Markets for Orthopedic Biomaterials 2013 - Millenium Research Group report. December 2012